{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Class (Stereo):
CHEMICAL (UNKNOWN)
Quintiofos is phosphonothioic ester derivative patented by Farbenfabriken Bayer A.-G. as insecticide and ascaricide, particularly against parasites of the larger animals.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ramnodigin is a cardenolide derivative patented by Farbwerke Hoechst A.-G. as cardiotonic, diuretic, and antidiarrheic compound. In in vitro studies, Ramnodigin shows cytotoxicity against nonsmall cell human lung cancer cells.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tabilautide (also known as RP 56142) is a tripeptide derivative patented by Rhone-Poulenc Industries S. A. as an immune adjuvant. In preclinical studies, Tabilautide displays potent protective activities against bacterial infections such as K. pneumoniae, L. monocytogenes or S. Typhimurium. Besides that Tabilautide shows antimetastatic activity and induces macrophage activation and enhanced cytotoxicity of natural killer cells in spleen, blood, and liver. These activities correlate with prophylactic and therapeutic effects of Tabilautide on artificial liver metastases of histiocytosarcoma.
Status:
Investigational
Source:
NCT01593761: Phase 2 Interventional Completed Skin Infection
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
CG-400549, also known as CG-0549, is an enoyl-(acyl-carrier protein) reductase fabl inhibitor developed by CrystalGenomics for the treatment of compcolicated acute and methicillin-resistant Staphylococcus aureus. CG400549 shows potent antimicrobial activity against 203 S. aureus strains and was more potent than either linezolid or vancomycin. An animal study showed that CG-400549has potential for the treatment of staphylococcal infections in mice and rats
Status:
Investigational
Source:
INN:cinepazic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ceftioxide is broad-spectrum , beta-lactam antibiotic patented by German pharmaceutical company Hoechst A.-G.
Class (Stereo):
CHEMICAL (ACHIRAL)
Amitivir [LY217896], an amino thiadiazole derivative, is an inhibitor of the enzyme inosine monophosphate dehydrogenase. Amitivir has activity against several influenza A and B viruses. Amitivir possesses broad antiviral activity in vitro and in animal models against or thomyxo-and paramyxoviruses. In phase I studies with healthy volunteers, single doses of up to 500 mg were well tolerated and had predictable pharmacokinetics. Oral LY217896 was in trial for prevention of experimental influenza A virus infection and illness in humans. LY217896 was associated with asymptomatic rises in serum uric acid levels and was ineffective in modifying the virologic or clinical course of experimental influenza A (H1N1) virus infection. Amitivir development was discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative. In the United States it is classified as a Schedule I controlled drug.
Status:
Investigational
Source:
NCT01977755: Phase 2 Interventional Completed Focus of Study is STEMI
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Danegaptide (GAP-134) is a small dipeptide gap junction modifier, developed by Wyeth and Zealand Pharma. Danegaptide works by re-establishing of gap junction intercellular communications in adjacent cardiomyocytes, thus reversing cardiac conduction slowing and electrical heterogeneity thought to be responsible for arrhythmias. In a canine model of acute sterile pericarditis, Danegaptide significantly reduced AF duration and overall AF burden. Danegaptide was investigated in phase 2 clinical trial in patients with ST-segment elevation myocardial infarction (STEMI). It was found that administrations danegaptide to patients with STEMI did not improve myocardial salvage, and development of the drug was discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Decitropine is an anticholinergic and antiulcer agent, developed by Koninklije Pharma FAB NV in the 1960s.
